Central Nervous System Viral Diseases: Clinical Trials

134 completed, 33 unknown, 24 recruiting, 9 not yet recruiting. 51 Phase 2, 45 Phase 3, 35 Phase 4, 19 Phase 1, 17 Not applicable.

By phase and status

Phase	Trials	Status
Phase 2	51	Completed 29, Unknown 9, Recruiting 5, Terminated 4, Not yet recruiting 3, Active not recruiting 1
Phase 3	45	Completed 40, Unknown 3, Not yet recruiting 1, Recruiting 1
Phase 4	35	Completed 26, Unknown 5, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Terminated 1
Phase 1	19	Completed 10, Not yet recruiting 2, Recruiting 2, Terminated 2, Withdrawn 2, Unknown 1
Not applicable	17	Completed 7, Unknown 4, Recruiting 3, Withdrawn 2, Not yet recruiting 1
Early Phase 1	2	Completed 2

Follow Central Nervous System Viral Diseases: new trials by email Literature Review of Central Nervous System Viral Diseases trials Research Report on Central Nervous System Viral Diseases

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Pain Phenotyping of Rheumatic Diseases - An Observational Study Bedside quantitative sensory testing - Rheumatic Diseases, Lupus Erythematosus, Systemic		Not yet recruiting	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	225	2026-10-27	2026-10-22
Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex BV100 with 50 mg polymyxin B plus ceftazidime/avibactam, BV100 with 50 mg polymyxin B plus cefiderocol, Best Available Therapy (BAT) - Ventilator Associated Bacterial Pneumonia (VABP), Hospital Acquired Bacterial Pneumonia (HABP)	Phase 2	Not yet recruiting	BioVersys AG	120	2026-07-01	2026-02-24
Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study Brincidofovir - Progressive Multifocal Leukoencephalopathy	Phase 2	Recruiting	National Institute of Neurological Disorders and Stroke (NINDS)	24	2026-06-05	2026-07-22
Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia Ozanimod - Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy		Recruiting	Bristol-Myers Squibb	15	2026-06-04	2026-07-29
Aciclovir Versus Placebo for HSV-2 Meningitis Acyclovir 50 MG/ML, Placebo - Herpes Simplex 2, Meningitis, Viral	Phase 4	Not yet recruiting	Jacob Bodilsen	150	2026-06-01	2025-10-01
Clinical Features and Outcomes of VZV CNS Infections Varicella Zoster, Varicella Meningitis		Completed	Kocaeli University	59	2026-04-17	2026-10-07
Prediction of Infectious Agents in the Biofire® FilmArray bioMérieux Meningitis/Encephalitis Panel Based on Clinical Syndrome and Cerebrospinal Fluid Parameters: a Diagnostic Stewardship Proposal. Biofire FilmArray Meningitis/Encephalitis Panel - Meningitis, Encephalitic Infection	Not applicable	Recruiting	Federal University of Health Science of Porto Alegre	182	2026-04-13	2026-08-21
Acute Treatment and Long-term Assessment of Adult Infectious Meningitis Viral Meningitis, Bacterial Meningitis		Recruiting	Hospital Israelita Albert Einstein	624	2026-03-30	2026-08-13
Prospective Clinical Registry of Acute Treatment and Long-term Assessment of Children Meningitis Meningitis, Bacterial Infections		Recruiting	Hospital Israelita Albert Einstein	600	2026-03-29	2026-05-05
T-cell Therapy in Patients With PML Application of T-lymphocytes - Progressive Multifocal Leucoencephalopathy (PML)	Phase 2	Recruiting	Hannover Medical School	23	2026-02-06	2026-10-15
First-in-Human Study Testing a New Antibody Treatment for Tick-Borne Encephalitis in Healthy Volunteers. Human monoclonal antibody TBE025, intravenous infusion - The Tick-borne Encephalitis Virus (TBEV)	Phase 1	Not yet recruiting	Giuseppe Pantaleo	18	2026-01-01	2026-01-29
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective Dengue, Chikungunya		Recruiting	Institut Pasteur du Cambodge	10000	2025-12-18	2026-01-22
Diagnostics and Surveillance of Acute Meningo-encephalitis Among Children in Cambodia With a Focus on Japanese Encephalitis Virus Japanese Encephalitis		Not yet recruiting	ANRS, Emerging Infectious Diseases	4000	2025-10-15	2025-09-11
Adjunctive Doxycycline for Central Nervous System Tuberculosis Doxycycline, Placebo, Anti Tuberculosis Drug - Tuberculosis, Meningeal, Tuberculosis; Meningitis (Etiology)	Phase 2	Recruiting	National University Hospital, Singapore	200	2025-08-21	2026-06-01
A Phase 1 Study Evaluating the Safety, Tolerability, and Immunogenicity of V4020 Vaccine in Healthy Volunteers V4020 - Venezuelan Equine Encephalitis, Venezuelan Equine Encephalitis Virus Infection	Phase 1	Not yet recruiting	Medigen, Inc.	39	2025-08-15	2025-07-28
High-Titer Neutralizing Plasma for West Nile Fever in Hospitalized Patients Plasma - West Nile Fever	Phase 2	Recruiting	Gili Regev-Yochay MD	37	2025-07-30	2025-08-26
A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine MVA-BN-WEV, Placebo - Encephalitis	Phase 2	Active not recruiting	Bavarian Nordic	411	2025-03-10	2025-10-01
Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases Peripheral venous blood sample - Leishmaniasis, Leptospirosis	Not applicable	Not yet recruiting	University Hospital, Montpellier	183	2025-03-03	2025-03-05
Molecular Epidemiology of Enteroviruses Detected at the Virology Laboratory of Brest University Hospital During the Period 2018-2024: Retrospective Analysis of an Atypical Meningitis Epidemic in 2024 (BrEcho9Men) Enterovirus Infections, Meningitis, Viral		Active not recruiting	University Hospital, Brest	270	2025-03-01	2025-04-10
A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults GBP560-A, GBP560-B, IXIARO - Japanese Encephalitis Virus Disease	Phase 1 / Phase 2	Completed	SK Bioscience Co., Ltd.	161	2025-02-24	2026-09-11

Showing 20 of 221. Sign in to see all of them.

Narrower conditions

Encephalitis, Japanese (72)  ·  Encephalitis, Tick-Borne (50)  ·  Leukoencephalopathy, Progressive Multifocal (29)  ·  Encephalitis (23)  ·  Meningitis (12)  ·  West Nile Fever (12)  ·  Acquired Immunodeficiency Syndrome (9)  ·  Meningitis, Viral (9)  ·  Encephalomyelitis, Venezuelan Equine (8)  ·  Cerebral Ventriculitis (7)  ·  Lupus Vasculitis, Central Nervous System (7)  ·  Multiple Sclerosis (7)  ·  Virus Diseases (7)  ·  Encephalitis, Viral (6)  ·  HIV Infections (6)

Broader conditions

Neuroinflammatory Diseases (220)  ·  Infections (219)  ·  Nervous System Diseases (218)  ·  Central Nervous System Diseases (216)  ·  Central Nervous System Infections (216)  ·  Brain Diseases (212)  ·  Virus Diseases (191)  ·  Encephalitis (190)  ·  Infectious Encephalitis (184)  ·  Encephalitis, Viral (180)  ·  RNA Virus Infections (160)  ·  Vector Borne Diseases (147)  ·  Arbovirus Infections (146)  ·  Encephalitis, Arbovirus (146)

Interventions

Japanese Encephalitis Vaccines (10)  ·  Vaccines (10)  ·  Blood Specimen Collection (6)  ·  Doxycycline (4)  ·  Desiccation (3)  ·  FSME-IMMUN vaccine (3)  ·  Hepatitis A Vaccines (3)  ·  Immunoglobulins, Intravenous (3)  ·  Saline Solution (3)  ·  Surveys and Questionnaires (3)  ·  Acyclovir (2)  ·  Dexamethasone (2)  ·  Didanosine (2)  ·  Immune Checkpoint Inhibitors (2)  ·  Measles-Mumps-Rubella Vaccine (2)

Sponsors

Pfizer (19)  ·  Valneva Austria GmbH (15)  ·  Sanofi Pasteur, a Sanofi Company (13)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (9)  ·  PATH (7)  ·  Sanofi (7)  ·  University Medical Centre Ljubljana (7)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (6)  ·  U.S. Army Medical Research and Development Command (6)  ·  Biogen (5)  ·  Novartis (5)  ·  Liaoning Chengda Biotechnology CO., LTD (3)  ·  Medical University of Vienna (3)  ·  National Institute of Hygiene and Epidemiology, Vietnam (3)  ·  University Hospital, Strasbourg, France (3)

Countries

United States (57)  ·  Germany (24)  ·  Austria (17)  ·  France (16)  ·  China (13)  ·  Poland (9)  ·  Australia (8)  ·  Thailand (8)  ·  Philippines (7)  ·  Slovenia (7)  ·  Czechia (6)  ·  Sweden (6)  ·  Vietnam (6)  ·  South Korea (5)  ·  Brazil (4)

Top investigators

Irene CM Cortese, M.D. (4)  ·  Astrid Kaltenboeck, Ph.D. (3)  ·  Ryszard Konior, MD (3)  ·  Thiem D Vu, MD., PhD. (3)  ·  Anna Durbin, MD (2)  ·  Anthony Cardile, DO (2)  ·  Huanyu Wang (2)  ·  Jerzy Brzostek, MD (2)  ·  Jerzy Dziduch, MD (2)

Results publications

PMID 20934459, PMID 21592984, PMID 28545923, PMID 15714427, PMID 18190252, PMID 18394765, PMID 19143532, PMID 20813797, PMID 20856164, PMID 20864814, PMID 21148499, PMID 21150279, PMID 21288804, PMID 21398392, PMID 21738597, PMID 22696017, PMID 22777096, PMID 23733308, PMID 23967083, PMID 24656175, PMID 24687904, PMID 24717964, PMID 24873986, PMID 25149833, PMID 25232151, PMID 25239483, PMID 25308927, PMID 25483480, PMID 25567119, PMID 25728316, PMID 25872531, PMID 25886645, PMID 26005163, PMID 26994987, PMID 27206386, PMID 27628323, PMID 27686833, PMID 27815383, PMID 27903416, PMID 28135273, PMID 29081368, PMID 29325161, PMID 29429815, PMID 30304652, PMID 30801037, PMID 30833160, PMID 30928173, PMID 30962094, PMID 32156630, PMID 32474892

NIH funding

2005 (1), 2008 (1), 2009 (1), 2019 (1), 2023 (1), U01CK000176 (1)